A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk Neuroblastoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03033303|
Recruitment Status : Recruiting
First Posted : January 26, 2017
Last Update Posted : February 5, 2019
|Condition or disease||Intervention/treatment||Phase|
|Neuroblastoma||Biological: Hu3F8 Drug: GM-CSF Drug: Isotretinoin||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||59 participants|
|Intervention Model:||Single Group Assignment|
|Intervention Model Description:||In this phase II single arm trial, patients with HR-NB in first CR or VGPR undergo consolidation by using hu3F8/GM-CSF.|
|Masking:||None (Open Label)|
|Official Title:||Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin for Consolidation of First Remission of Patients With High-Risk Neuroblastoma: A Phase II Study|
|Actual Study Start Date :||January 23, 2017|
|Estimated Primary Completion Date :||June 2022|
|Estimated Study Completion Date :||June 2022|
Experimental: Hu3F8/GM-CSF Plus Isotretinoin
In this phase II single arm trial, patients with HR-NB in first CR or VGPR undergo consolidation by using hu3F8/GM-CSF x5 cycles and isotretinoin x6 cycles. Isotretinoin starts after cycle 2 of hu3F8/GM-CSF.
Day 1: hu3F8 infused iv over ~30 to 90 minutes. Day 3: hu3F8 infused iv over ~30 to 90 minutes. Day 5: hu3F8 infused iv over ~30 to 90 minutes.
Days -4 to 0: GM-CSF 250 mcg/m2/day, subcutaneously. Days 1 to 5: GM-CSF 500 mcg/m2/day, subcutaneously.
Isotretinoin is administered at 160 mg/m2/d, divided into two doses, x14 days.
- relapse-free survival (RFS) [ Time Frame: 2 years ]Patients are considered a response failure under this protocol if progressive disease is evident before two years. Deaths from toxicity attributable to protocol treatment will be counted as events. Patients who withdraw or are lost to followup before two years will be considered as progressions.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03033303
|Contact: Brian H. Kushner, MDfirstname.lastname@example.org|
|Contact: Shakeel Modak, MD||212-639-7623|
|United States, New York|
|Memorial Sloan Kettering Cancer Center||Recruiting|
|New York, New York, United States, 10065|
|Contact: Brian H. Kushner, MD 212-639-6793|
|Contact: Shakeel Modak, MD 212-639-7623|
|Principal Investigator: Brian H. Kushner, MD|
|Principal Investigator:||Brian H. Kushner, MD||Memorial Sloan Kettering Cancer Center|